Photo of Joe Lennerz from pathologyoutlines.com
Apr 12, 2024, 05:34
Joe Lennerz: Quickly sharing a fantastic paper on tumour infiltrating lymphocytes in triple-negative breast cancer
Joe Lennerz, Chief Scientific Officer at BostonGene, shared on LinkedIn:
“Quickly sharing a fantastic paper on tumour infiltrating lymphocytes (TIL) in triple-negative breast cancer (TNBC). Bottom line: In patients with early-stage TNBC who did not undergo adjuvant or neoadjuvant chemotherapy, breast cancer tissue with a higher abundance of TIL levels was associated with significantly better survival.
These results suggest that breast tissue TIL abundance is a prognostic factor for patients with early-stage TNBC. Link to publication.”
Source: Joe Lennerz/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 7, 2025, 18:04
Jan 7, 2025, 18:04
Jan 7, 2025, 18:03
Jan 7, 2025, 17:59
Jan 7, 2025, 17:54